Nanoparticles for drug delivery: the need for precision in reporting particle size parameters.

Polymeric drug-loaded nanoparticles have been extensively studied in the field of drug delivery. Biodistribution depends on the physicochemical properties of particles, especially size. The global message from the literature is that small particles have an enhanced ability to reach their target. The present review highlights the difficulties in validating the data from biodistribution studies without accurate particle size determination.

[1]  H. Wadenvik,et al.  The spleen and pooling of blood cells , 1988, European journal of haematology.

[2]  Ying-Ying Lin,et al.  Highly efficient approach for characterizing nanometer-sized gold particles by capillary electrophoresis , 2005 .

[3]  G. Winter,et al.  Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. , 2004, Analytical chemistry.

[4]  T. Kawanami,et al.  Electron microscopy of the blood‐brain barrier in disease , 1994, Microscopy research and technique.

[5]  J. L. Turner,et al.  An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. , 2005, Biomacromolecules.

[6]  P. N. Prasad,et al.  Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery , 2003 .

[7]  Robert Gurny,et al.  Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .

[8]  K. Landfester,et al.  Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. , 2006, Biomaterials.

[9]  R. Müller,et al.  Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. , 2001, International journal of pharmaceutics.

[10]  M. Mayberg,et al.  A new dynamic in vitro model for the multidimensional study of astrocyte–endothelial cell interactions at the blood–brain barrier , 2002, Brain Research.

[11]  H. Kawaguchi,et al.  Functional polymer microspheres , 2000 .

[12]  L. Seymour.  Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.

[13]  K. Arfors,et al.  Microvascular transport of macromolecules in normal and inflammatory conditions. , 1979, Acta physiologica Scandinavica. Supplementum.

[14]  M. Akashi,et al.  Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[15]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[16]  A. Maitra,et al.  Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[17]  R. Gurny,et al.  pH-Dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs , 2001, AAPS PharmSci.

[18]  B. Hirst,et al.  Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. , 1993, Journal of drug targeting.

[19]  Hsing-Wen Sung,et al.  Preparation of nanoparticles composed of chitosan/poly-gamma-glutamic acid and evaluation of their permeability through Caco-2 cells. , 2005, Biomacromolecules.

[20]  E. Debefve,et al.  Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. , 2006, Journal of photochemistry and photobiology. B, Biology.

[21]  S. Moghimi,et al.  Exploiting bone marrow microvascular structure for drug delivery and future therapies , 1995 .

[22]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Gabizon,et al.  Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. , 1995, Journal of neurosurgery.

[24]  B. Gander,et al.  In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  A. Hoffman,et al.  Formulation of chitosan-DNA nanoparticles with poly(propyl acrylic acid) enhances gene expression , 2004, Journal of biomaterials science. Polymer edition.

[26]  W. Tiyaboonchai,et al.  Insulin containing polyethylenimine-dextran sulfate nanoparticles. , 2003, International journal of pharmaceutics.

[27]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[28]  Y. Takakura,et al.  Extravasation of macromolecules. , 1998, Advanced drug delivery reviews.

[29]  Si-Shen Feng,et al.  Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[30]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[31]  O. Bourdon,et al.  Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. , 2001, Biomaterials.

[32]  H. Aboul‐Enein,et al.  In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. , 2004, Chirality.

[33]  E. Nakache,et al.  Polymer Nanoparticle Characterization in Aqueous Suspensions , 2002 .

[34]  Jianhua Hu,et al.  Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. , 2005, International journal of pharmaceutics.

[35]  T. Heath,et al.  Equivalent pore estimate for the alveolar-airway barrier in isolated dog lung. , 1988, Journal of applied physiology.

[36]  Nicholas A Peppas,et al.  Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[37]  K. Avgoustakis,et al.  Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.

[38]  Z. Zhou,et al.  In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. , 2005, International journal of pharmaceutics.

[39]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[40]  K. Higaki,et al.  Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[41]  S. Davis,et al.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[42]  V. Vogel,et al.  Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  A. Maitra,et al.  Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. , 2000, International journal of pharmaceutics.

[44]  H. S. Oh,et al.  A Polymeric Nanoparticle Consisting of mPEG-PLA-Toco and PLMA-COONa as a Drug Carrier: Improvements in Cellular Uptake and Biodistribution , 2005, Pharmaceutical Research.

[45]  Hong-Zhuan Chen,et al.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  Jong-sang Park,et al.  Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. , 2002, Arthritis and rheumatism.

[47]  Shohei Sugimoto,et al.  Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[48]  K. Avgoustakis,et al.  Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. , 2003, International journal of pharmaceutics.

[49]  V. Labhasetwar,et al.  Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. , 2002, International journal of pharmaceutics.

[50]  N. Elvassore,et al.  Nisin-loaded poly-L-lactide nano-particles produced by CO2 anti-solvent precipitation for sustained antimicrobial activity. , 2004, International journal of pharmaceutics.

[51]  V. Labhasetwar,et al.  Characterization of nanoparticle uptake by endothelial cells. , 2002, International journal of pharmaceutics.

[52]  H. Kaş.  Drug delivery to brain by microparticulate systems. , 2004, Advances in experimental medicine and biology.

[53]  R. Gurny,et al.  Cell interaction studies of PLA-MePEG nanoparticles. , 2003, International journal of pharmaceutics.

[54]  Marek Romanowski,et al.  Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[55]  I. Oh,et al.  Physicochemical characterization of poly(L-lactic acid) and poly(D,L-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier. , 2005, International journal of pharmaceutics.

[56]  M. Wirth,et al.  WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[57]  Maria José Alonso,et al.  Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.

[58]  P. Legrand,et al.  Polyester-Poly(Ethylene Glycol) Nanoparticles Loaded with the Pure Antiestrogen RU 58668: Physicochemical and Opsonization Properties , 2003, Pharmaceutical Research.

[59]  F. Vrečer,et al.  Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. , 2002, International journal of pharmaceutics.

[60]  Y. Ikada,et al.  Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification , 1997 .

[61]  R. Müller,et al.  The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. , 1987, Life sciences.

[62]  S. Davis,et al.  The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. , 2001, Biochimica et biophysica acta.

[63]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[64]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[65]  A. Maitra,et al.  Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. , 2002, International journal of pharmaceutics.

[66]  T. Delair,et al.  Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. , 2005, Colloids and surfaces. B, Biointerfaces.

[67]  Dennis E. Koppel,et al.  Analysis of Macromolecular Polydispersity in Intensity Correlation Spectroscopy: The Method of Cumulants , 1972 .

[68]  F. Zanella,et al.  Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. , 2002, Toxicology letters.

[69]  M. Ogris,et al.  Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. , 2003, International journal of pharmaceutics.

[70]  U. Bakowsky,et al.  Preparation and characterization of cationic PLGA nanospheres as DNA carriers. , 2004, Biomaterials.

[71]  Mansoor M. Amiji,et al.  BIODEGRADABLE POLY (E-CAPROLACTONE) NANOPARTICLES FOR TUMOR-TARGETED DELIVERY OF TAMOXIFEN , 2002 .

[72]  C. Fong,et al.  Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[73]  H. Cölfen.  Analytical ultracentrifugation of nanoparticles , 2004 .

[74]  S. Moghimi.  Mechanisms of splenic clearance of blood cells and particles : towards development of new splenotropic agents , 1995 .

[75]  M. Hashida,et al.  Important role of serum proteins associated on the surface of particles in their hepatic disposition. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[76]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[77]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[78]  T. Park,et al.  Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. , 2004, Journal of pharmaceutical sciences.